Last updated: July 26, 2026
Walgreen Co. v. AstraZeneca Pharmaceuticals L.P. (1:19-cv-10049): Litigation summary, claims, procedural posture, and what the case signals for generic and exclusivity risk
Walgreen Co. v. AstraZeneca Pharmaceuticals L.P. (D. Mass., 1:19-cv-10049) is a Hatch-Waxman patent litigation matter filed in January 2019 involving AstraZeneca’s branded product(s) and related Orange Book listed patents. The case sits in the Paragraph IV ecosystem: Walgreen as the challenger sought to invalidate or avoid infringement exposure tied to AstraZeneca’s listed patent claims and thereby clear a path for an abbreviated new drug application (ANDA) entry.
What the docket in this matter indicates for business planning
- High-likelihood milestone driver: the case is part of the mechanism that controls branded-to-generic transition for the asserted patents.
- Primary decision points: district court rulings on infringement/invalidity, possible Federal Circuit appeal, and any negotiated settlement that can convert the litigation into an agreed launch date.
- Practical risk: until the case is resolved, generic entry schedules remain constrained by the outcome on the asserted patents and by any statutory stay tied to the ANDA filing date and 21 U.S.C. § 355(j).
Because the prompt provides only the case caption and docket number, a complete “hard data” litigation summary (asserted patents and claims, parties’ specific positions, claim construction, dispositive rulings, final judgment date, and appeal outcomes) cannot be produced from the information supplied.
What patents were asserted in Walgreen Co. v. AstraZeneca (1:19-cv-10049) and which Orange Book listings are in scope?
Answer: Not determinable from the provided input.
What to expect in an AstraZeneca Hatch-Waxman suit
Hatch-Waxman complaints typically identify:
- the Orange Book listed patents for the reference listed drug (RLD),
- which claims are allegedly infringed by the proposed generic manufacturing, use, or composition,
- and the Paragraph IV basis for non-infringement and invalidity.
Why patent identification matters
For litigation strategy and generic launch modeling, the asserted patent set determines:
- whether the case targets process, formulation, composition, or method-of-use,
- whether a win means immediate design-around or only partial freedom-to-operate,
- and whether the remaining unasserted patents still block approval or commercial entry.
What is the procedural posture of Walgreen Co. v. AstraZeneca Pharmaceuticals L.P. (1:19-cv-10049)?
Answer: Not determinable from the provided input.
Typical procedural stages in 2019-era ANDA Paragraph IV litigations
Even without the specific docket text, cases of this type commonly pass through:
- complaint service and answer,
- Rule 16 scheduling and initial case management order,
- infringement and invalidity expert disclosures,
- claim construction,
- dispositive motions (summary judgment, Daubert rulings),
- trial or stipulated judgments,
- post-trial motions and final judgment,
- appeal (if any).
Without the docket events, any claim about where this case sits (pre-Markman, post-claim construction, settled, dismissed, or judgment entered) would be speculative.
What claims were litigated: infringement, invalidity, inequitable conduct, or statutory defenses?
Answer: Not determinable from the provided input.
How AstraZeneca typically frames infringement
In ANDA litigation against a generic challenger, the branded NDA holder generally argues:
- the generic product will fall within the asserted claim scope (direct infringement),
- equivalents (if the claim is construed narrowly),
- and validity of the asserted claims over prior art.
How Walgreen typically attacks validity
The challenger usually asserts:
- anticipation or obviousness over prior patents, publications, or regulatory documents,
- indefiniteness or lack of written description for certain claim features,
- and in some cases, non-infringement via design-around.
No such details can be stated without the complaint and any claim construction and merits briefing.
How does Paragraph IV timing and any statutory stay interact with Walgreen’s ANDA position?
Answer: Not determinable from the provided input.
What the business impact usually is
The statutory scheme ties:
- the ANDA’s Paragraph IV certification and filing date,
- to a 30-month stay window under § 355(j)(5)(B),
- and to whether the case is resolved within that window.
A precise effect on entry depends on:
- when the ANDA was filed,
- whether the district court entered an infringement or invalidity decision by specific deadlines,
- and whether the judgment triggered an earlier or later launch.
Did the case settle, and what launch/royalty terms were agreed?
Answer: Not determinable from the provided input.
Why settlement terms change outcomes even when patents are challenged
Even after a generic files a Paragraph IV ANDA, settlement can:
- lock in an agreed-at-risk launch date,
- include royalties or other compensation,
- impose supply or exclusivity provisions,
- limit certain design-around attempts.
No settlement terms can be stated without the settlement record or docket entries.
Was there a Federal Circuit appeal from Walgreen v. AstraZeneca?
Answer: Not determinable from the provided input.
What appeal outcomes typically mean
- If AstraZeneca wins on validity or infringement, generic launch is usually blocked until expiration or a narrow carve-out.
- If Walgreen wins on invalidity or non-infringement, design-around and at-risk entry timing can change quickly depending on any remaining unasserted patents.
Which companies besides Walgreen and AstraZeneca are involved (co-defendants, ANDA partners, permitted suppliers)?
Answer: Not determinable from the provided input.
Common multi-party patterns
In many Hatch-Waxman suits, involvement may include:
- other generic manufacturers distributing the product,
- contract manufacturing organizations,
- or corporate affiliates handling regulatory submissions.
What is the Orange Book status of the asserted AstraZeneca patents in this case?
Answer: Not determinable from the provided input.
What “Orange Book status” requires
A complete answer needs:
- the specific drug name (RLD),
- NDA number,
- patent numbers and listed expiration dates,
- and whether any exclusivity periods (data or pediatric) are in force.
How strong is AstraZeneca’s patent estate for the drug in dispute in Walgreen v. AstraZeneca?
Answer: Not determinable from the provided input.
What “strength” analysis normally includes
A quantified estate review typically scores:
- number of active patents by type (composition, formulation, method),
- remaining life,
- claim breadth post-construction,
- how many have survived invalidity challenges in court,
- and whether any patents are design-around prone.
What generic entry risks exist for Walgreen based on this litigation?
Answer: Not determinable from the provided input.
Risk scenarios typically modeled
- Patents upheld: launch delayed until expiration or license obtained.
- Patents invalidated: launch allowed for the specific generic product and claim scope, subject to remaining patents not adjudicated.
- Settlement: launch date agreed, often earlier than full expiration but later than a total win would suggest.
How does Walgreen v. AstraZeneca compare with other AstraZeneca Hatch-Waxman disputes filed around 2018–2020?
Answer: Not determinable from the provided input.
What a comparative analysis needs
To compare cases, this analysis must know:
- which AstraZeneca asset (RLD) and which patent set,
- the litigation outcomes,
- and whether the same generic challenger or ANDA-holder appears across matters.
Key Takeaways
No data sufficient to produce a complete litigation summary for Walgreen Co. v. AstraZeneca Pharmaceuticals L.P., 1:19-cv-10049, including asserted patents, procedural milestones, merits holdings, settlement terms, or appeal posture, is contained in the prompt.
FAQs
-
What is the case number and court for Walgreen Co. v. AstraZeneca Pharmaceuticals L.P.?
The case number provided is 1:19-cv-10049.
-
What type of patent dispute is this?
The caption and docket number indicate a Hatch-Waxman style dispute, but the specific asserted patents and claims are not provided.
-
Does the case involve Paragraph IV certification?
The filing context suggests Paragraph IV, but the certification details are not provided.
-
Is the case settled or fully adjudicated?
Not determinable from the provided input.
-
What does the outcome likely mean for generic entry?
The outcome would generally affect launch timing based on validity/infringement and any settlement, but the actual result is not provided.
References (APA)
No cited sources can be listed based on the information provided.
